We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New Britain, Pa.-based Thrombolex said its endovascular-thrombolytic delivery system cleared 90 percent of totally occluded pulmonary arteries in an interim analysis from a pivotal trial. Read More
Sweden’s Xvivo touted the success of its heart perfusion device used in the first successful transplantation of a genetically modified pig heart to a human. Read More
Alpha Tau Medical said its alpha-radiation cancer therapy device Alpha DaRT produced complete tumor responses in all 10 patients treated in a multi-center U.S. trial. Read More
Rapid antigen COVID-19 testing in adults doesn’t identify as many early infections as reverse-transcriptase polymerase chain-reaction (RT-PCR), but in children, accuracy was quite high, two new studies have found. Read More
The first biopolymer heart valve, developed by Foldax USA, has passed initial human trials and is ready for deployment into a larger study population, the company said. Read More
Immunicom presented preliminary data from a clinical trial investigating a potential therapy for resistant melanoma and other solid cancers using an external blood-filtering device, showing that the treatment is safe and well-tolerated. Read More
Several major manufacturers of tests for the SARS-CoV-2 virus that causes COVID-19 are saying their products will detect infections caused by the new Omicron variant first identified in South Africa and now spreading rapidly around the world. Read More
Patients with treatment-resistant high blood pressure who were treated with ReCor Medical’s Paradise ultrasound renal denervation system — which uses radiofrequency ablation to burn the nerves in the renal arteries — maintained lower blood pressure over six months in a clinical trial, the company said. Read More
AbbVie’s investigational subcutaneous ABBV-951( foslevodopa/foscarbidopa) delivery system racked up impressive numbers in a pivotal 12-week phase 3 study for patients with advanced Parkinson’s disease. Read More